Core Viewpoint - Four Seasons Pharmaceutical (00460) experienced a nearly 9% increase in stock price, closing at 1.75 HKD, following the announcement of its product approval by the National Medical Products Administration of China [1] Group 1: Product Approval - The company’s subsidiary, Meiyan Space Biotechnology (Jilin) Co., Ltd., received a Class III medical device registration certificate for its self-developed injectable transparent sodium hyaluronate composite solution, branded as "Dongyan" [1] - "Dongyan" is the first approved compound solution in China that contains L-carnosine, designed for temporary improvement of skin dryness and dull complexion [1] Group 2: Strategic Product Matrix - The approval of "Dongyan" marks another milestone for Meiyan Space, following the earlier launches of "Tongyan Injection" and "Shaonian Injection" within the year [1] - The company is building a strategic product matrix that combines compliant regenerative materials (Tongyan and Shaonian injections) with skin quality management (water light needle) as dual engines [1] Group 3: Market Position - Meiyan Space has over thirty approved products, establishing a comprehensive product layout in the light medical beauty sector [1] - The company has achieved an integrated layout from skin quality improvement to contour modification, reinforcing its leading position in comprehensive anti-aging solutions [1]

Core Viewpoint - The approval of the injectable transparent sodium hyaluronate composite solution "Dongyan" marks a significant milestone for the company, enhancing its product portfolio in the aesthetic medicine sector [1][2] Group 1: Product Development - "Dongyan" is the first approved injectable solution containing L-carnosine in China, designed to temporarily improve skin dryness and dull complexion [1] - The product's key ingredients include sodium hyaluronate, L-carnosine, vitamin B2, glycine, alanine, and proline, which collectively support skin hydration, antioxidant properties, and collagen regeneration [1] Group 2: Strategic Positioning - The approval of "Dongyan" follows the earlier launches of "Tongyan" and "Shaonv" needles, further establishing a dual-engine strategic product matrix focused on compliant regenerative materials and skin quality management [2] - The company has over thirty approved products, creating a comprehensive product layout in the light medical beauty sector, from skin quality improvement to contour modification [2] Group 3: Future Plans - The company plans to increase investment in aesthetic medicine research and development, leveraging its nationwide sales network to promote "Dongyan" and enhance brand building [2] - The goal is to provide safer, more advanced, and personalized aesthetic services, leading the high-quality development of the Chinese aesthetic medicine industry [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 Sihuan Pharmaceutical Holdings Group Ltd. 四環醫藥控股集團有限公司 （於百慕達註冊成立的有限公司） （股份代號：0460） 自願公告 四環醫藥旗下渼顏空間自主研發的 含L－肌 肽 的 複 合 溶 液 水 光 針「凍 妍」 獲得國家藥監局批准上市 四 環 醫 藥 控 股 集 團 有 限 公 司（「本公司」或「四環醫藥」，連 同 其 附 屬 公 司，統 稱 為「本集團」）董 事 會（「董事會」）欣 然 宣 佈，本 集 團 旗 下 渼 顏 空 間 生 物 科 技（吉 林） 有 限 公 司（「渼顏空間」）自 主 研 發 的 注 射 用 透 明 質 酸 鈉 複合溶液（商 品 名：凍 妍， 「該產品」）正 式 獲 得 中 國 國 家 藥 品 監 督 管 理 局（「國家藥監局」）頒 發 第 三 類 醫 療 器 械 註 冊 ...